Bergstrom Donald A sold $1.6M of RLAY
Bergstrom Donald A (President, R&D) sold 93,456 shares of Relay Therapeutics, Inc. (RLAY) at $16.94 ($1.58M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale by an R&D president under a pre-arranged 10b5-1 plan; it does not include any new guidance, trial results, contracts, or regulatory actions.
Market read
Traders may monitor insider activity for sentiment, but this specific disclosure is unlikely to change valuation without accompanying fundamental news.
What to watch
The article does not state whether other insiders or the company also made concurrent disclosures, nor does it provide post-sale changes in options or compensation structure.
Background
The article is a SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics disclosed a Form 4 showing President of R&D Donald Bergstrom sold 93,456 shares at $16.94 on a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven rather than fundamentals.
The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and the article provides no new company-specific operational or financial developments.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Insider sales on 10b5-1 plans often reflect liquidity planning rather than bearish expectations, so the market may overreact to the headline framing.
Key entities
- issuerRelay Therapeutics, Inc.
Company subject of the Form 4 insider transaction disclosure.
- insiderDonald A. Bergstrom
President, R&D, who sold shares under a 10b5-1 plan.